Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Payables (2016 - 2026)

Iradimed has reported Payables over the past 14 years, most recently at $2.2 million for Q1 2026.

  • Quarterly Payables fell 15.75% to $2.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.2 million through Mar 2026, down 15.75% year-over-year, with the annual reading at $1.8 million for FY2025, 4.01% down from the prior year.
  • Payables was $2.2 million for Q1 2026 at Iradimed, up from $1.8 million in the prior quarter.
  • Over five years, Payables peaked at $9.8 million in Q4 2023 and troughed at $822118.0 in Q2 2022.
  • The 5-year median for Payables is $1.8 million (2025), against an average of $2.2 million.
  • Year-over-year, Payables skyrocketed 446.49% in 2023 and then crashed 80.72% in 2024.
  • A 5-year view of Payables shows it stood at $1.8 million in 2022, then skyrocketed by 446.49% to $9.8 million in 2023, then crashed by 80.72% to $1.9 million in 2024, then dropped by 4.01% to $1.8 million in 2025, then rose by 19.89% to $2.2 million in 2026.
  • Per Business Quant, the three most recent readings for IRMD's Payables are $2.2 million (Q1 2026), $1.8 million (Q4 2025), and $2.3 million (Q3 2025).